Evidence map›Paper›PMID 38987686›Full record

ArticleBMC immunology2024

Neutralizing antibody responses assessment after vaccination in people living with HIV using a surrogate neutralization assay.

Armel Landry Batchi-Bouyou, Jean Claude Djontu, Line Lobaloba Ingoba, Jiré Séphora Mougany, Freisnel Hermeland Mouzinga, Jacques Dollon Mbama Ntabi, Franck Yannis Kouikani, Arcel Christ Massamba Ndala, Steve Diafouka-Kietela, Raoul Ampa and 1 more

Abstract read
In one paragraph

Article in BMC immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Armel Landry Batchi-BouyouFondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo. a.batchi-bouyou@wustl.edu.
Jean Claude DjontuFondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo.
Line Lobaloba IngobaFondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo.
Jiré Séphora MouganyFondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo.
Freisnel Hermeland MouzingaFondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo.
Jacques Dollon Mbama NtabiFondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo.
Franck Yannis KouikaniDepartment of Health and Social Care, Ministry of Higher Education, Scientific Research and Technological Innovation, Brazzaville, Republic of the Congo.
Arcel Christ Massamba NdalaAmbulatory Treatment Center, National HIV Program, Ministry of Health and Population, Brazzaville, Republic of the Congo.
Steve Diafouka-KietelaFondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo.
Raoul AmpaFaculty of Sciences and Techniques, University Marien Ngouabi, Brazzaville, Republic of the Congo.
Francine NtoumiFondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo. fntoumi@fcrm-congo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHIV has been reported to interfere with protective vaccination against multiple pathogens, usually through the decreased effectiveness of the antibody responses. We aimed to assess neutralizing antibody responses induced by COVID-19 vaccination in PLWH in Brazzaville, Republique of the Congo.

methodThe study was conducted at the Ambulatory Treatment Center of the National HIV Program, in charge of over 6000 PLWH, and the health center of FCRM in Brazzaville, Republic of the Congo. Participants were divided into two groups: PLWH with well-controlled HIV infection (CD4 counts no older than one week ≥ 800 / mm

resultsWe collected oropharyngeal and blood samples from 1016 participants including 684 PLWH and 332 PLWOH. Both PLWH and PLWOH elicited high levels of antibody responses after complete vaccination with inactivated virus vaccine (Sinopharm/BBIP-CorV) and adenovirus-based vaccines (Janssen/Ad26.COV2.S and Sputnik/Gam-COVID-Vac). Overall, no difference was observed in neutralization capacity between PLWOH and PLWH with well-controlled HIV infection.

conclusionThe results from this study underline the importance of implementing integrated health systems that provide PLWH the opportunity to benefit HIV prevention and care, at the same time while monitoring their vaccine-induced antibody kinetics for appropriate booster schedules.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesHIV InfectionsSARS-CoV-2VaccinationAdultFemaleHumansMaleMiddle AgedNeutralization TestsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesAntibodiesJanssen/Ad26.COV2.SRepublic of the CongoSARS-CoV-2Sinopharm/BBIP-CorVVaccine

Identifiers

PMID38987686
PMCPMC11234560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.